Friday, January 31, 2025 | 10:44 PM ISTEN Hindi
Business Standard
Notification Icon
userprofile IconSearch

Page 3 - Biocon

Stocks to watch: Adani Enterprises, Dish TV, Infosys, Hindustan Copper

Stocks to watch today: Adani Enterprises subsidiary raised over Rs 6,000 crore to set up greenfield copper refinery; State-run IOB will boost advances across retail, corporate and MSME loans this year

Stocks to watch: Adani Enterprises, Dish TV, Infosys, Hindustan Copper
Updated On : 27 Jun 2022 | 8:02 AM IST

CBI arrests Jt Drug Controller, Biocon Biologics execs over fishy approvals

All five apprehended will be presented in court on Tuesday afternoon, agency to seek police custody

CBI arrests Jt Drug Controller, Biocon Biologics execs over fishy approvals
Updated On : 22 Jun 2022 | 2:31 AM IST

SEC recommendation in accordance with guidelines: Biocon Biologics

The company said its product approvals are backed by science and clinical data

SEC recommendation in accordance with guidelines: Biocon Biologics
Updated On : 22 Jun 2022 | 1:15 AM IST

Joint drugs controller nabbed taking bribe to clear Biocon unit's injection

The CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, Director at Synergy Network India Private Limited, among others.

Joint drugs controller nabbed taking bribe to clear Biocon unit's injection
Updated On : 20 Jun 2022 | 10:58 PM IST

Biocon hits over two-year low; slips 18% in six weeks post weak Q4 results

In the past one year, the stock has slipped 22 per cent, as against a 39 per cent rally in the S&P BSE Sensex.

Biocon hits over two-year low; slips 18% in six weeks post weak Q4 results
Updated On : 08 Jun 2022 | 11:55 AM IST

CCI approves Serum Institute Life Sciences-Biocon Biologics deal

The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies and Biocon Biologics. Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator. Covidshield Technologies Pvt Ltd (CTPL), a wholly-owned subsidiary of Serum Institute of Life Sciences, will be merged into Biocon Biologics. In a tweet on Wednesday, the watchdog said it has cleared the "merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences." CTPL was incorporated to undertake the business of marketing, selling and distributing vaccines, drugs and other pharmaceutical products. Biocon Biologics Ltd is a subsidiary of Biocon Ltd. It offers treatment for chronic and acute diseases such as

CCI approves Serum Institute Life Sciences-Biocon Biologics deal
Updated On : 19 May 2022 | 5:59 PM IST

Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon

Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening

Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon
Updated On : 19 May 2022 | 8:27 AM IST

Ireland regulator reports manufacturing deficiency at Biocon's plant

Biocon Biologics is a subsidiary of Biocon Ltd

Ireland regulator reports manufacturing deficiency at Biocon's plant
Updated On : 04 May 2022 | 1:59 AM IST

BJP hits out at Kiran Shaw for keeping mum on students carrying Bibles

The BJP used the signing of MoU for setting up the largest semiconductor fabrication unit in Karnataka to hit out at Shaw

BJP hits out at Kiran Shaw for keeping mum on students carrying Bibles
Updated On : 02 May 2022 | 12:47 PM IST

Biocon Q4 consolidated net profit declines by 4% to Rs 283 crore

Biocon's consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period

Biocon Q4 consolidated net profit declines by 4% to Rs 283 crore
Updated On : 28 Apr 2022 | 10:53 PM IST

F&O expiry: Nifty ends April series above 17,200; Sensex gains 702 pts

As of 06:50 AM, the SGX Nifty April futures quoted at 17,066. According to analysts, the April series has been one of the most volatile series for the Nifty in recent times. The options data.

F&O expiry: Nifty ends April series above 17,200; Sensex gains 702 pts
Updated On : 28 Apr 2022 | 3:34 PM IST

BJP accuses Biocon chief of imposing personal, politically coloured opinion

The BJP accused her of imposing personal and 'politically coloured' opinion and conflating it with India's leadership in Information technology and biotechnology sectors

BJP accuses Biocon chief of imposing personal, politically coloured opinion
Updated On : 31 Mar 2022 | 4:14 PM IST

Biocon Executive Chairperson Kiran Mazumdar-Shaw elected as RSE fellow

Mazumdar-Shaw, who is also the Executive Chairperson of Biocon Biologics, will be joining RSE's current fellowship of around 1,700 fellows, the company said in a statement

Biocon Executive Chairperson Kiran Mazumdar-Shaw elected as RSE fellow
Updated On : 23 Mar 2022 | 6:47 PM IST

Biocon Biologics to go for IPO in 18-24 months: Kiran Mazumdar-Shaw

Biocon arm buys Viatris biosimilars biz for $3.2 billion

Biocon Biologics to go for IPO in 18-24 months: Kiran Mazumdar-Shaw
Updated On : 28 Feb 2022 | 11:30 PM IST

Biocon beefs up biosimilar portfolio with $3.3-bn Viatris deal, shares fall

The company in a statement said that its subsidiary Biocon Biologics has inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.335 billion

Biocon beefs up biosimilar portfolio with $3.3-bn Viatris deal, shares fall
Updated On : 28 Feb 2022 | 6:37 PM IST

Sensex ends 1,414 pts off low, gains 389 pts; Tata Steel rises 6%, RIL 3%

Closing Bell: Hindalco (up over 7 per cent), Tata Steel, Power Grid, JSW Steel, Coal India, BPCL, Titan Company, RIL, and Indian Oil Corporation were the biggest large-cap gainers on the bourses today

Sensex ends 1,414 pts off low, gains 389 pts; Tata Steel rises 6%, RIL 3%
Updated On : 28 Feb 2022 | 3:45 PM IST

Biocon arm plans to acquire Viatris' biosimilars assets; stock falls 8%

The companies will also enter into a transition services agreement. Viatris will provide certain transition services, including commercialization services for an expected 2-years

Biocon arm plans to acquire Viatris' biosimilars assets; stock falls 8%
Updated On : 28 Feb 2022 | 12:02 PM IST

Biocon Biologics acquires Viatris' biosimilars business in $3.3 bn deal

BBL will also obtain Viatris' rights in all biosimilars assets, including its in-licensed portfolio and an option to acquire Viatris' rights in bAflibercept

Biocon Biologics acquires Viatris' biosimilars business in $3.3 bn deal
Updated On : 28 Feb 2022 | 12:55 AM IST

Rahul Bajaj: Mahindra, Mazumdar-Shaw among industry leaders to pay tribute

Industry leaders on Saturday paid rich tributes to noted industrialist Rahul Bajaj (83) who passed away due to illness at his home in Pune. Taking to Twitter, Mahindra Group Chairman Anand Mahindra stated: I stand on the shoulders of giants. Thank you, Rahulbhai, for letting me clamber up onto your broad shoulders, advising me, cheering me on, encouraging me to be bold. Your footprints on the sands of Indian Business will never be extinguished." Biocon Executive Chairperson Kiran Mazumdar-Shaw tweeted: "Industrialist Rahul Bajaj, Former Chairman Of Bajaj Group, Dies At 83 - I am devastated - he was a dear dear friend and will miss him dearly. The country has lost a great son & nation builder." TVS Motor Company Chairman Venu Srinivasan stated that Bajaj strode across the Indian industrial landscape like a colossus. "He was among the few stars who created the Indian automotive industry. He was a pioneer who established a culture of quality and technology. He stood for high ...

Rahul Bajaj: Mahindra, Mazumdar-Shaw among industry leaders to pay tribute
Updated On : 12 Feb 2022 | 6:34 PM IST

Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks

Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.

Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks
Updated On : 08 Feb 2022 | 11:14 AM IST